Weekly Research Analysts’ Ratings Changes for Danaher (DHR)

Several brokerages have updated their recommendations and price targets on shares of Danaher (NYSE: DHR) in the last few weeks:

• 4/25/2026 – Danaher was downgraded by Wall Street Zen from “buy” to “hold”.
• 4/24/2026 – Danaher had its price target lowered by Argus from $265.00 to $230.00. They now have a “buy” rating on the stock.
• 4/22/2026 – Danaher had its price target lowered by Morgan Stanley from $270.00 to $255.00. They now have an “overweight” rating on the stock.
• 4/22/2026 – Danaher had its price target lowered by Morgan Stanley from $270.00 to $255.00. They now have an “overweight” rating on the stock.
• 4/22/2026 – Danaher had its price target lowered by UBS Group AG from $270.00 to $250.00. They now have a “buy” rating on the stock.
• 4/22/2026 – Danaher had its price target lowered by JPMorgan Chase & Co. from $275.00 to $245.00. They now have an “overweight” rating on the stock.
• 4/22/2026 – Danaher had its price target lowered by Wells Fargo & Company from $240.00 to $212.00. They now have an “equal weight” rating on the stock.
• 4/22/2026 – Danaher had its price target lowered by TD Cowen from $245.00 to $240.00. They now have a “buy” rating on the stock.
• 4/22/2026 – Danaher had its price target lowered by Guggenheim from $275.00 to $235.00. They now have a “buy” rating on the stock.
• 4/21/2026 – Danaher had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $245.00 price target on the stock.
• 4/21/2026 – Danaher had its price target raised by Evercore Inc from $225.00 to $232.00. They now have an “outperform” rating on the stock.
• 4/17/2026 – Danaher had its price target lowered by Robert W. Baird from $251.00 to $249.00. They now have an “outperform” rating on the stock.
• 4/17/2026 – Danaher was given a new $205.00 price target by Rothschild & Co Redburn.
• 4/14/2026 – Danaher had its price target lowered by Barclays PLC from $250.00 to $230.00. They now have an “overweight” rating on the stock.
• 4/13/2026 – Danaher had its price target lowered by TD Cowen from $270.00 to $245.00. They now have a “buy” rating on the stock.
• 4/13/2026 – Danaher had its price target lowered by The Goldman Sachs Group, Inc. from $265.00 to $230.00. They now have a “buy” rating on the stock.
• 4/8/2026 – Danaher had its price target lowered by Jefferies Financial Group Inc. from $265.00 to $240.00. They now have a “buy” rating on the stock.
• 4/8/2026 – Danaher had its price target lowered by Wolfe Research from $260.00 to $230.00. They now have an “outperform” rating on the stock.
• 4/6/2026 – Danaher had its price target lowered by Evercore Inc from $254.00 to $225.00. They now have an “outperform” rating on the stock.
• 3/27/2026 – Danaher had its “hold (c)” rating reaffirmed by Weiss Ratings.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Friday, June 26th. Danaher’s payout ratio is currently 30.95%.

Insider Buying and Selling at Danaher

In related news, EVP Gregory M. Milosevich sold 1,320 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $208.01, for a total value of $274,573.20. Following the completion of the sale, the executive vice president owned 5,099 shares of the company’s stock, valued at approximately $1,060,642.99. This represents a 20.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 10.80% of the company’s stock.

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.